Adam Crum obo SciClone Pharmaceuticals v. Friedhelm Blobel; Gary Titus; Jon Saxe

     SciClone executives inflated shares by lying about the business, operation and prospects of developing treatments for cancer and infectious diseases in China and other international markets, a derivative investor claims.

%d bloggers like this: